7773.Two
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with a current ratio of 19.93, indicating a high ability to meet short-term obligations. However, the company reported negative operating and net income, with operating income at -47.8 million TWD and net income at -38.9 million TWD, suggesting operational challenges. The return on equity and return on assets are both negative, at -7.07% and -6.82%, respectively, indicating poor capital efficiency and asset utilization compared to industry benchmarks.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, reflecting minimal leverage and a conservative financing approach. This is supported by a total equity of 550.7 million TWD and total liabilities of 20.7 million TWD. Despite this, the company's operating cash flow is negative at -23.7 million TWD, and free cash flow is also negative at -30.4 million TWD, indicating a cash outflow from operations.
The company's revenue is concentrated in a single segment, as disclosed in the financial snapshot, with no additional segment details provided. The geographic exposure is not specified, but the company's operations are primarily in Taiwan, given the TWD financial reporting. There is no indication of significant geographic diversification or multiple business segments contributing to revenue.
The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The negative operating and net income, combined with negative cash flows, suggest a challenging operating environment. The capital expenditure of -768,000 TWD indicates minimal investment in new assets, which may limit future growth potential.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong equity position contribute to its low liquidity risk. However, the negative operating performance and cash flows may pose long-term sustainability concerns. There are no indications of dilution pressure in the near term, as the number of shares outstanding remains unchanged between basic and diluted shares.
Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The company's financial statements and disclosures do not highlight any material risks or events that would alter the current assessment.
- The company has a strong liquidity position with a current ratio of 19.93.
- The company is experiencing operational losses, with negative operating and net income.
- The company maintains a conservative capital structure with a low debt-to-equity ratio.
- The company's growth trajectory is uncertain due to negative cash flows and minimal capital expenditure.
- The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
- "margin_outlook_rationale": "The company's margin outlook is negative due to the reported negative operating and net income.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 7773.TWO Market data — financials · 2026-05-27